The Global Biopharmaceutical Contract Manufacturing Industry, valued at approximately US$ 9.3 billion in 2022, is set to experience robust growth at a Compound Annual Growth Rate (CAGR) of 10.5%. It is expected to reach a staggering US$ 18.7 billion by 2029. This meteoric rise reflects the growing trend among pharmaceutical companies to outsource their biopharmaceutical …